Multiple endocrine neoplasia type 1 epidemiology and demographics: Difference between revisions
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The prevalence of multiple endocrine neoplasia type-1 is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop | The prevalence of [[multiple endocrine neoplasia]] type-1 ([[MEN, type 1|MEN]]-1) is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop [[Multiple endocrine neoplasia type 1|MEN-1]], but it is commonly diagnosed among patients between 18-50 years of age. [[Multiple endocrine neoplasia type 1|MEN-1]] affects men and women equally. There is no racial predilection to multiple endocrine neoplasia type-1. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== |
Revision as of 18:47, 3 October 2017
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 epidemiology and demographics |
FDA on Multiple endocrine neoplasia type 1 epidemiology and demographics |
CDC on Multiple endocrine neoplasia type 1 epidemiology and demographics |
Multiple endocrine neoplasia type 1 epidemiology and demographics in the news |
Blogs on Multiple endocrine neoplasia type 1 epidemiology and demographics |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [3]
Overview
The prevalence of multiple endocrine neoplasia type-1 (MEN-1) is approximately 2-3 per 100,000 individuals worldwide. Patients of all age groups may develop MEN-1, but it is commonly diagnosed among patients between 18-50 years of age. MEN-1 affects men and women equally. There is no racial predilection to multiple endocrine neoplasia type-1.
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of multiple endocrine neoplasia type 1 is estimated to be 2-3 per 100,000.[1]
Age
- Endocrine and non-endocrine manifestations of the disease in multiple endocrine neoplasia type 1 patients most often begin in the fourth or fifth decade. The onset of the disease is rare before 10 years of age.[2][3]
Gender
- Men and women are affected equally by multiple endocrine neoplasia type 1.[2][4]
- Men have a higher incidence of pancreatic tumors, whereas women have a higher incidence of pituitary tumors.
- Thymic tumors are common among men.
Race
- The prevalence of multiple endocrine neoplasia type 1 does not vary by race.
References
- ↑ [1] C. Romei, E. Pardi, F. Cetani, and R. Elisei, “Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2,” Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036
- ↑ 2.0 2.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/j.beem.2010.07.003 Check
|pmid=
value (help). - ↑ Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E; et al. (2006). "Multiple endocrine neoplasia type 1". Orphanet J Rare Dis. 1: 38. doi:10.1186/1750-1172-1-38. PMC 1594566. PMID 17014705.
- ↑ Goudet P, Bonithon-Kopp C, Murat A, Ruszniewski P, Niccoli P, Ménégaux F; et al. (2011). "Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines". Eur J Endocrinol. 165 (1): 97–105. doi:10.1530/EJE-10-0950. PMID 21551167.